Exemestane Hilma Biocare

Exemestane by Hilma Biocare, best known under the brand name Aromasin, is a potent steroidal aromatase inhibitor used to lower estrogen levels in the body. In the athletic community it is run to manage and prevent the estrogen-related side effects of anabolic steroid use — gynecomastia, water retention and blood-pressure spikes — while keeping hormonal balance intact throughout a cycle. Because it binds irreversibly to the aromatase enzyme, its effect is steady and does not rebound the way non-steroidal inhibitors can.
| Active substance | Exemestane |
| Manufacturer | Hilma Biocare |
| Form | Oral tablets |
| Typical dosage | 12.5–25 mg every other day |
| Class | Steroidal aromatase inhibitor |
| Primary use | Estrogen control on cycle and PCT |
Effects and benefits
As a suicidal aromatase inhibitor, Exemestane permanently disables the enzyme that converts testosterone into estrogen, which makes it effective at controlling bloat and gyno without crashing lipids as harshly as some alternatives. Athletes value its predictable, dose-dependent control.
- Reduces circulating estrogen effectively
- Prevents and treats gynecomastia
- Cuts water retention and puffiness
- Supports a leaner, drier look on cycle
Dosage and administration
Most users run 12.5–25 mg every other day, titrating to symptoms and bloodwork rather than fixed numbers. As an ancillary it belongs in any structured post cycle therapy and on-cycle support plan rather than in the anabolic stack itself.
Stacking and combinations
Depending on the aromatizing load of a cycle, Exemestane is often chosen over or rotated with other inhibitors such as Anastrozole, while Letrozole is kept in reserve for heavier gyno management.
Why choose Hilma Biocare
Every batch is produced to consistent pharmaceutical standards with dependable dosing you can trust for estrogen control. Explore the complete Hilma Biocare catalogue to assemble a matching support protocol.
| Characteristics | |
| Shelf Life | 36 months from manufacture date |
| Drug Class | Aromatase Inhibitor |
| Concentration | Typically 25 mg per tablet |
| Half-Life | Approximately 24 hours |
| Detection Time | Not typically tested in standard drug screenings |
| Active Substance | Exemestane |
| Dosage | 12.5-25 mg per day |
| Drug Category | Post Cycle Therapy |
| Form | Oral tablets |
| Product Packaging | 30 tablets |
| Progestational Activity | None |
| Liver Toxicity | Low |
| Chemical Structure | C20H24O2 |
| Estrogenic Activity | Antagonist |
